The discovery of vanadyl and zinc complexes for treating diabetes and metabolic syndromes

Expert Opinion on Drug Discovery

Volumn 2, Issue 6, 2007, Pages 873-887

  Sakurai, Hiromu ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Adiponectin; Coordination environment; Diabetes; Metabolic syndrome; Structure activity relationship; Vanadyl complex; Zinc complex

Indexed keywords

ANTIBODY; ANTIDIABETIC AGENT; ASCORBIC ACID; ETHYLMALTOL; GLUTATHIONE; INSULIN; MALTOL; MALTOLATE ZINC; NEW DRUG; ORAL ANTIDIABETIC AGENT; OXOVANADIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANADATE SODIUM; VANADIC ACID; VANADIUM; VANADIUM DERIVATIVE; VANADYL DERIVATIVE; VANADYL MALONATE; VANADYL METHYLCYSTEINATE; VANADYL OXALATE; VANADYL PICOLINATE; VANADYL PYRROLIDINEDITHIOCARBAMATE; VANADYL SALICYLALDEHYDE; VANADYL SULFATE; VANADYL TARTRATE; ZINC; ZINC CHLORIDE; ZINC COMPLEX; ZINC DERIVATIVE; ZINC DITHIOCARBAMATE;

ANTIBODY PRODUCTION; CELL DESTRUCTION; DIABETES MELLITUS; DIABETOGENESIS; DIET RESTRICTION; DISEASE CLASSIFICATION; DRUG DESIGN; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; EXERCISE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SYNTHESIS; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 34548087943     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.6.873     Document Type: Review

References (106)

1. REAVEN GM: Role of insulin resistance in human disease. Diabetes (1988) 37(12):1595-1607.
2. KAPLAN NM: The deadly quartet. Arch. Intern. Med. (1989) 149(7):1514-1520.
3. MATSUZAWA Y: The metabolic syndrome and adipocytokines. FEBS Lett. (2006) 580(12):2917-2921.
4. KERSHAW EE, FILIER JS: Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. (2004) 89(6):2548-2556.
5. BANTING FG, BEST CH: The internal secretion of the pancreas. J. Lab. Clin. Med. (1922) 7:251-266.
6. World Health Organization: Definition, diagnosis and classification of diabetes mellitus and its complications, Part 1: Diagnosis and classification of diabetes mellitus. Department of noncommunicable disease surveillance, Geneva (1999).
7. LYONNET B, MARTZ X, MARTIN E: Ĺemploi thèrapeutique des derives du vanadium. Presse Med.(1899) 1(32):191-192.
8. TOLMAN EL, BARRIS E, BURNS M, PRASINI R, PARTRIDGE R: Effect of vanadium on glucose metabolism in vitro. Life Sci. (1979) 25(13):1159-1164.
9. DUBYAK GR, KLEINZELLER A: The insulin-mimetic effects of vanadate in isolated rat adipocytes. J. Biol. Chem. (1980) 255(11):5306-5312.
10. SHECHTER Y, KARLISH SJD: Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl(IV) ions. Nature (1980) 284(5756):556-558.
11. TAMURA S, BROWN TA, DUBLER RF, LARNER J: Insulin-like effect of vanadate on adipocytes glucogen synthase and on phosphorylation of 95,000 dalton submit of insulin receptor. Biochem. Biophys. Res. Commun. (1983) 113(1):80-86.
12. HEYLIGER CE, TAHILIANI AG, MCNEILL JH: Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science (1985) 227(4693):1474-1477.
13. MEYEROVITCH J, FARFEL Z, SACK J, SHECHTER Y: Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. J. Biol. Chem. 262(14):6658-6662.
14. ZENZ C: Vanadium. In: Metals in the Environment. Waldron HA (Ed.), Academic Press, New York, USA (1980):293-327.
15. REHDER D: Biological and medical aspects of vanadium. Inorg. Chem. Commun. (2003) 6(5):604-617.
16. CRANS DC, SMEE JJ, GAIDAMAUSKAS E, YANG L: The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds. Chem. Rev. (2004) 104(2):849-902.
17. - by ascorbic acid and glutathione: kinetic studies of pro-drugs for the enhancement of insulin action. Inorg. Chem. (2002) 41(6):1357-1364.
18. PEDERSON RA, RAMANADHAM S, BUCHAN AMJ, MCNEILL JH: Long-term effects of vanadyl treatment on streptozocin-induced diabetes in rats. Diabetes (1989) 38(11):1390-1395.
19. MONGOLD JJ, CROS GH, VIAN L et al.: Toxicological aspects of vanadyl sulfate on diabetic rats: effects of vanadium levels and pancreatic β-cell morphology. Pharmacol. Toxical. (1990) 67(3):192-198.
20. RAMANADHAM S, CROS GH, MONGOLD JJ, SERRANO JJ, MCNEILL JH: Enhanced in vivo sensitivity of vanadyl-treated diabetic rats to insulin. Can. J. Physiol. Pharmacol. (1990) 68(4):486-491.
21. SAKURAI H, TSUCHIYA K, NUKATSUKA M, SOFUE M, KAWADA J: Insulin-like effect of vanadyl ion on streptozotocin-induced diabetic rats. J. Endocrinol. (1990) 126(3):451-459.
22. SAKURAI H, TSUJI A: Antidiabetic action of vanadium complexes in animals: blood glucose normalizing effect, organ distribution of vanadium, and mechanism for insulin-mimetic action. In: Vanadium in the Environment (Part 2) Health Effects. Nriagu JO (Ed.), John Wiley & Sons, Toronto, Canada (1998):297-325.
23. SAKURAI H, KOJIMA Y, YOSHIKAWA Y, KAWABE K, YASUI H: Antidiabetic vanadium(IV) and zinc(II) complexes. Coord. Chem. Rev. (2002) 226(1-2):187-198.
24. SAKURAI H: A new concept: the use of vanadium complexes in the treatment of diabetes mellitus. Chem. Rec. (2002) 2(4):237-248.
25. SAKURAI H, YASUI H, ADACHI Y: The therapeutic potential of insulin-mimetic vanadium complexes. Expert Opin. Investig. Drugs (2003) 12(7):1189-1203.
26. SAKURAI H, KATOH A, YOSHIKAWA Y: Chemistry and biochemistry of insulin-mimetic vanadium and zinc complexes. Trial for treatment of diabetes mellitus. Bull. Chem. Soc. Jpn. (2006) 79(11):1645-1664.
27. THOMPSON KH, MCNEILL JH, ORVIG C: Vanadium compounds as insulin mimics. Chem. Rev. (1999) 99(9):2561-2572.
28. THOMPSON KH, ORVIG C: Vanadium in diabetes: 100 years from Phase 0 to Phase I. J. Inorg. Biochem. (2006) 100(12):1925-1935.
29. SAKURAI H, TSUCHIYA K, NUKATSUKA M et al.: Insulin-mimetic action of vanadyl complexes. J. Clin. Biochem. Nutr. (1990) 8(3):193-200.
30. MCNEILL JH, YUEN VG, HOVEYDA HR, ORVIG C: Bis(maltolato)oxovanadium(IV) is a potent insulin mimetic. J. Med. Chem. (1992) 35(8):1489-1491.
31. WATANABE H, NAKAI M, KOMAZAWA K, SAKURAI H: A new orally active insulin-mimetic vanadyl complex: bis(pyrrolidine-N-carbodithioato) oxovanadium(IV). J. Med. Chem. (1994) 37(7):876-877.
32. SAKURAI H, WATANABE H, TAMURA H, YASUI H, MATSUSHITA R, TAKADA J: Insulin-mimetic vanadyl-dithiocarbamate complexes. Inorg. Chim. Acta (1998) 283(1):175-183.
33. SAKURAI H, FUJII K, WATANABE H, TAMURA H: Orally active and long-term acting insulin-mimetic vanadyl complex: bis(picolinato)oxovanadium(IV). Biochem. Biophys. Res. Commun. (1995) 214(3):1095-1101.
34. 2O)]. Chem. Lett. (1998) 27(1):9-10.
35. KAWABE K, TADOKORO M, ICHIMURA A, KOJIMA Y, TAKINO T, SAKURAI H: Streospecific and structure-dependent insulin-mimetic oxovanadium(IV) complexes with N,N′-ethylene-bis(amino acids). J. Am. Chem. Soc. (1999) 121(34):7937-7938.
36. 2) coordination mode. Chem. Lett. (1999) 28(9):913-914.
37. 2) coordination mode. J. Inorg. Biochem. (2001) 85(2-3):179-186.
38. SAKURAI H, INOHARA T, ADACHI Y, KAWABE K, YASUI H, TAKEDA J: A new candidate for insulinomimetic vanadium complex: synergism of oxovanadium(IV)-porphyrin and sodium ascorbate. Bioorg. Med. Chem. Lett. (2004) 14(5):1093-1096.
39. SAHA TK, ADACHI Y, YOSHIKAWA Y, YASUI H, SAKURAI H: A new type of orally active insulin-mimetic vanadylporphyrin complex: (meso-tetrakis(4-sulfon atophenyl)porphyrinato)oxovanadium(IV). Chem. Lett. (2005) 34(10):1350-1351.
40. SAHA TK, YOSHIKAWA Y, YASUI H, SAKURAI H: Oxovanadium(IV)-porphyrin complex as a potent insulin-mimetic. Treatment of experimental type 1 diabetic mice by the complex (meso-tetrakis(4-sulfonatophenyl)porphyrin ato)oxovanadium(IV) (4-). Bull. Chem. Soc. Jpn. (2006) 79(8):1191-1200.
41. y mice by oral treatment with (meso-tetrakis(4-sulfonatophe nyl)porphyrinato)oxovanadium(IV)(4-) complex. J. Pharm. Pharmacol. (2007) 59(3):437-444.
42. WOO LCY, YUEN VG, THOMPSON KH, MCNEILL JH, ORVIG C: Vanadyl-biguanide complexes as potential synergistic insulin mimics. J. Inorg. Biochem. (1999) 76(3-4):251-257.
43. FUJIMOTO S, FUJII K, YASUI H, MATSUSHITA R, TAKADA J, SAKURAI H: Long-term acting and orally active vanadyl-methylpicolinate complex with hypoglycemic activity in streptozotocin-induced diabetic rats. J. Clin. Biochem. Nutr. (1997) 23(2):113-129.
44. y mice with daily oral administration of bis(6-methylpicolina to)oxovanadium(IV) complex. Chem. Pharm. Bull. (1999) 47(11):1668-1670.
45. TAKINO T, YASUI H, YOSHITAKE A et al.: A new halogenated antidiabetic vanadyl complex, bis(5-iodopicolina to) oxovanadium(IV): in vitro and in vivo insulinomimetic evaluations and metallokinetic analysis. J. Biol. Inorg. Chem. (2001) 6(2):133-142.
46. SAKURAI H, TAMURA A, TAKINO T, OZUTSUMI K, KAWABE K, KOJIMA Y: Interaction of vanadyl complexes with biological systems: structure-insulinomimetic activity relationship of vanadyl-picolinate complexes. Inorg. Reac. Meehan. (2000) 2(1-2):69-77.
47. y mice. J. Inorg. Biochem. (2002) 88(1):108-112.
48. 2hpic). Chem. Lett. (2002) 31(9):916-917.
49. NAKAI M, OBATA M, SEKIGUCHI F et al.: Syntheses and insulinomimetic activities of novel mono- and tetranuclear oxovanadium(IV) complexes with 3-hydroxpyridine-2-carboxylic acid. J. Inorg. Biochem. (2004) 98(1):105-112.
50. KISS E, PETROHÁN K, SANNA D, GARRIBBA E, MICERA G, KISS T: Solution speciation and spectral studies on oxovanadium(IV) complexes of pyridinecarboxylic acid. Polyhedron (2000) 19(1):55-61.
51. KISS E, BENYEI A, KISS T: VO(IV) complexes of 3-hydroxypicolinic acid: a solution study and the structure of a supramolecular assembly in the solid state. Polyhedron (2003) 22(1):27-33.
52. GÄTJENS J, MEIER B, KISS T et al.: A new family of insulin-mimetic vanadium complexes derived from 5-carboalkoxypicolinates. Chem. Eur. J. (2003) 9(20):4924-4935.
53. YASUI H, TAMURA A, TAKINO T, SAKURAI H: Structure-dependent metallokinetics of antidiabetic vanadyl-picolinate complexes in rats: studies on solution structure, insulinomimetic activity, and metallokinetics. J. Inorg. Biochem. (2002) 91(1):327-338.
54. YUEN VG, ORVIG C, MCNEILL JH: Improvement in cardic dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium(IV). Can. J. Physiol. Pharmacol. (1993) 71(3-4):263-269.
55. THOMPSON KH, LIBOIRON BD, SUN Y et al.: Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential. J. Biol. Inorg. Chem. (2003) 8(1-2):66-74.
56. ADACHI Y, YOSHIDA J, KODERA Y, KATOH A, TAKADA J, SAKURAI H: Bis(allixinato)oxovanadium(IV) complex is a potent antidiabetic agent: studies on structure-activity relationship for a series of hydroxypyrone-vanadium complexes. J. Med. Chem. (2006) 49(11):3251-3256.
57. y mice by bis(allixinato)oxov anadium(IV) complex. Biochem. Biophys. Res. Commun. (2006) 345(3):945-950.
58. CUSI K, CUKIER S, DEFRONZO RA, TORRES M, PUCHULU FM, REDONDO JCP: Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. J. Clin. Endocrinol. Metab. (2001) 86(3):1410-1417.
59. FUGONO J, YASUI H, SAKURAI H: Enteric-coating capsulation of insulinomimecic vanadyl sulfate enhances bioavailability of vanadyl species in rats. J. Pharm. Pharmacol. (2002) 54(5):611-615.
60. FUGONO J, YASUI H, SAKURAI H: Improvement of diabetic states in streptozotocin-induced type 1 diabetic rats by vanadyl sulfate in enteric-coated capsules. J. Pharm. Pharmacol. (2005) 57(5):665-669.
61. KARMAKER S, SAHA TK, YOSHIKAWA Y, YASUI H, SAKURAI H: A novel drug delivery system for type 1 diabetes: insulin-mimetic vanadyl-poly (γ-glutamic acid) complex. J. Inorg. Biochem. (2006) 100(9):1535-1546.
62. COULSTON L, DANDONA P: Insulin-like effect of zinc on adipocytes. Diabetes(1980) 29(8):665-557.
63. SHISHEVA A, GEFEL D, SCHECHTER Y: Insulin-like effects on zinc ion in vitro and in vivo. Diabetes (1992) 41(8):982-988.
64. SHARON FS, CARLA GT: Dietary zinc supplementation attenuates hyperglycemia in db/db mice. Exp. Biol. Med. (2001) 226(1):43-51.
65. SONG MK, ROSENTHAL MJ, HONG S et al.: Synergistic antidiabetic activities of zinc, cyclo (His-Pro), and arachiclonic acid. Metabolism (2001) 50(1):53-59.
66. CHEN MD, LIOU SJ, LIN PY, YANG VC, ALEXANDER PS, LIN WH: Effects of zinc supplementation on the plasma glucose level and insulin activity in genetically obese (ob/ob) mice. Biol. Trace Elem. Res. (1998) 61(3):303-311.
67. TALLMAN DL, TAYLOR CG: Potential interactions of zinc in the neuroendocrine-endocrine disturbances of diabetes mellitus type 2. Can. J. Physiol. Pharmacol. (1999) 77(12):919-933.
68. SIMON SF, TAYLOR CG: Dietary zinc supplementation attenuates hyperglycemia in db/db mice. Exper. Biol. Med. (2001) 226(1):43-51.
69. TAYLOR CG: Zinc, the pancreas, and diabetes: insights from rodent studies and future directions. BioMetals (2005) 18(4):305-312.
70. 4) coordination mode. Chem. Lett. (2000) 29(8):874-875.
71. y mice with type 2 diabetes mellitus Biochem. Biophys. Res. Commun. (2001) 281(5):1190-1193.
72. 2) coordination mode. Chem. Pharm. Bull. (2001) 49(5):652-654.
73. 2) coordination mode: structure characterization, in vitro, and in vivo studies. J. Biol. Inorg. Chem. (2002) 7(1-2):68-73.
74. UEDA E, YOSHIKAWA Y, ISHINO Y, SAKURAI H, KOJIMA Y: Potential insulinominetic agents of zinc(II) complexes with picolinamide derivatives: preparations of complexes, in vitro and in vivo studies. Chem. Pharm. Bull. (2002) 50(3):337-340.
75. FUGONO J, FUJIMOTO K, YASUI H et al.: Metallokinetic stury of zinc in the blood of normal rats given insulinomimetic zinc(II) complexes and improvement of diabetes mellitus in type 2 diabetic GK rats by their oral administration. Drug Metabol. Phrmacokin. (2002) 17(4):340-347.
76. KATOH A, TSUKAHARA T, SAITO R et al.: An extremely high insulin-mimetic activity of bis(1,4-dihydro-2-merhyl-l-phenyl-4-thioxo-3-pyridinolato)zinc(II) complex. Chem. Lett. (2002) 31(1):114-115.
77. YOSHIKAWA Y, KAWABE K, TADOKORO M et al.: New zinc(II) complexes with tetradentate amino acid derivatives: structure characterization, solution chemistry, and in vitro insulinomimetic activity. Bull. Chem. Soc. Jpn. (2002) 75(11):2423-2432.
78. YOSHIKAWA Y, UEDA E, SAKURAI I, KOJIMA Y: Anti-diabetes effect of Zn(II)/ carnitine complex by oral administration, Chem. Pharm. Bull. (2003) 51(2):230-231.
79. y mice with type 2 diabetes mellitus. Chem. Pharm. Bull. (2003) 51(8):1006-1008.
80. UEDA E, YOSHIKAWA Y, KISHIMOTO N et al.: New bioactive zinc(II) complexes with peptides and their derivatives: synthesis, structure, and in vitro insulinomimetic activity. Bull. Chem. Soc. Jpn. (2004) 77(5):981-986.
81. MATSUMOTO K, YAMAMOTO S, YOSHIKAWA Y et al.: Antidiabetic activity of Zn(II) complexes with a derivative of L-glutamine. Bull. Chem. Soc. Jpn. (2005) 78(6):1077-1081.
82. YOSHIKAWA Y, KONDO M, SAKURAI H, KOJIMA Y: A family of insulinomimetic zinc(II) complexes of amino ligands with Zn(Nn) (n = 3 and 4) coordination modes. J. Inorg. Biochem. (2005) 99(7):1497-1503.
83. 4) coordination mode. Chem. Lett. (2005) 34(12):1694-1695.
84. ADACHI Y, YOSHIDA J, KODERA Y et al.: A new insulin-mimetic bis(allixinato)zinc(II) complex: structure-activity relationship of zinc(II) complexes J. Biol. Inorg. Chem. (2004) 9(7):885-893.
85. 2) coordination mode: bis(1,6-dimethyl-3-hydroxy-5-methoxy-2-pentyl-1, 4-dihydropyridine-4-thionato)zinc(II). Chem. Lett. (2005) 34(5):656-657.
86. ADACHI Y, YOSHIDA J, KODERA Y et al.: Oral administration of a zinc complex improves type 2 diabetes and metabolic syndromes. Biochem. Biophys. Res. Commun. (2006) 351(1):165-170.
87. YOSHIKAWA Y, ADACHI Y, SAKURAI H: A new type of orally active anti-diabetic Zn(II)-dithiocarbamate complex. Life Sci. (2007) 80(8):759-766.
88. FANTUS IG, TSIANI E: Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects. Mol. Cell. Biochem. (1998) 182(1-2):109-119.
89. SHECHTER Y, GOLDWASER I, MIRONCHIK M, FRIDKIN M, GEFEL D: Historic perspective and recent developments on the insulin-like actions of vanadium; towards developing vanadium-based drugs for diabetes. Coord. Chem. Rev. (2003) 237(1-2):3-11.
90. SCIOR T, GUEVARA-GARCIA A, BERNARD P, DO Q-T, DOMEYER D, LAUFER S: Are vanadium compound drugable? Structure and effects of antidiabetic vanadium compound: a critical review. Mini-Rev. Med. Chem. (2005) 5(11):955-1008.
91. SALTIEL AR, KAHN CR: Insulin signaling and the regulation of glucose and lipid metabolism. Nature (2001) 414(6865):799-806.
92. HERMAN MA, KAHN BB: Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J. Clin. Invest. (2006) 116(7):1767-1775.
93. TANIGUCHI CM, EMANUELLI B, KAHN CR: Critical nodes in signaling pathway: insights into insulin action. Nat. Rev. Mol. Cell Biol. (2006) 7(2):85-96.
94. BRAZIL DP, HEMMINGS BA: Ten years of protein kinase B signaling: a hard Akt to fellow. Trends Biochem. Sci. (2001) 26(11):657-664.
95. KANZAKI M: Insulin receptor signals regulating GLUT4 translocation and actin dynamics. Endocrinol. J. (2006) 12:1-37.
96. OLSON AL, KNIGHT JB, PESSIN JE: Syntaxin 4, VAMP2, and/or VAMP3/ cellubrevin are functional target membrane and vesicle SNAP receptors for insulin-stimulated GLUT4 translocation in adipocytes. Mol. Cell Biol. (1997) 17(5):2425-2435.
97. BYON JCH, KUSARI AB, KUSARI J: Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Mol. Cell Biochem. (1998) 182(1&2):101-108.
98. BASUKI W, HIROMURA M, ADACHI Y, TAYAMA K, HATTORI M, SAKURAI H: Enhancement of insulin signaling pathway in adipocytes by oxovanadium(IV) complexes. Biochem. Biophy. Res. Commun. (2006) 349(3):1163-1170.
99. ZARGAR AH, BASHIR MI, MASOODI SR et al.: Copper, zinc and magnesium levels in type-1 diabetes mellitus. Saudi. Med. J. (2002) 23(5):539-542.
100. HO E, QUAN N, TSAI YH, LAI W, BRAY TM: Dietary zinc supplementation inhibits NF kapper β activation and protects against chemically induced diabetes in CD1 mice. Exp. Biol. Med. (2001) 226(2):103-111.
101. QURAISHI I, COLLINS S, PESTANER JF, HARRIS T, BAGASRA O: Role of zinc and transporters in the molecular pathogenesis of diabetes mellitus. Med. Hypotheses (2005) 65(5):887-892.
102. HAASE H, MARET W: Intracellular zinc fluctuations modulate protein tyrosine phosphatase activity in insulin/insulin-like growth factor-1 signaling. Exp. Cell Res. (2003) 291(2):289-298.
103. CUNNINGHAM JJ, FU A, MEARKLE PL, BROWN RG: Hyperzincuria in individuals with insulin-dependent diabetes mellitus: concurrent zinc status and the effect of high-dose zinc supplementation. Metabolism (1994) 43(12):1558-1562.
104. 2) enhances insulin signaling pathway in 3T3-L1 adipocytes. J. Inorg. Biochem. (2007) 101(4):692-699.
105. KAWABE K, YOSHIKAWA Y, ADACHI Y, SAKURAI H: Possible mode of action for insulinomimetic activity of vanadyl(IV) compound in adipocytes. Life. Sci. (2006) 78(24):2860-2866.
106. YOSHIKAWA Y, UEDA E, KOJIMA Y, SAKURAI H: The action mechanism of zinc(II) complexes with insulinomimetic activity in rat adipocytes. Life Sci. (2004) 75(6):741-751.